van den Berg, Joost H https://orcid.org/0000-0002-4928-8397
Heemskerk, Bianca
van Rooij, Nienke
Gomez-Eerland, Raquel
Michels, Samira
van Zon, Maaike
de Boer, Renate
Bakker, Noor A M
Jorritsma-Smit, Annelies
van Buuren, Marit M
Kvistborg, Pia
Spits, Hergen
Schotte, Remko
Mallo, Henk
Karger, Matthias
van der Hage, Joris A
Wouters, Michel W J M
Pronk, Loes M
Geukes Foppen, Marnix H
Blank, Christian U
Beijnen, Jos H
Nuijen, Bastiaan
Schumacher, Ton N
Haanen, John B A G
Clinical trials referenced in this document:
Documents that mention this clinical trial
Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up
https://doi.org/10.1136/jitc-2020-000848
Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial
https://doi.org/10.1136/jitc-2023-008372
Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report
https://doi.org/10.1136/bmjgast-2022-000989
Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes
https://doi.org/10.1136/jitc-2024-010575
TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy
https://doi.org/10.1136/jitc-2023-006847
Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
https://doi.org/10.1136/jitc-2020-000668